TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/19/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. TRMD
9. ACN
10. AZN

Go back to TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
TG THERAP (NASDAQ: TGTX) Delayed: 56.87 +0.40 (0.71%)
Previous Close $56.47    52 Week High $14.87 
Open $56.98    52 Week Low $4.90 
Day High $57.73    P/E N/A 
Day Low $56.18    EPS $-0.67 
Volume 5,168,992